IL96365A - Preparation for the treatment of inflammatory bowel disorders with C6-2 alkanoic acids - Google Patents

Preparation for the treatment of inflammatory bowel disorders with C6-2 alkanoic acids

Info

Publication number: IL96365A
Authority: IL; Israel
Prior art keywords: acid; composition; present; liter; inflammatory bowel
Prior art date: 1989-11-16

Application number

IL9636590A

Other languages

English (en)

Hebrew (he)

Other versions

IL96365A0 (en

Original Assignee

Breuer Richard L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-16

Filing date

1990-11-16

Publication date

1995-06-29

1990-11-16 Application filed by Breuer Richard L filed Critical Breuer Richard L

1991-08-16 Publication of IL96365A0 publication Critical patent/IL96365A0/xx

1995-06-29 Publication of IL96365A publication Critical patent/IL96365A/en

Links

230000002757 inflammatory effect Effects 0.000 title claims abstract description 17
239000000203 mixture Substances 0.000 title claims description 30
239000002253 acid Substances 0.000 title claims description 14
150000007513 acids Chemical class 0.000 title claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
208000024891 symptom Diseases 0.000 claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 34
208000035475 disorder Diseases 0.000 claims description 16
206010009900 Colitis ulcerative Diseases 0.000 claims description 13
201000006704 Ulcerative Colitis Diseases 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 11
208000011231 Crohn disease Diseases 0.000 claims description 8
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 8
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 8
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 7
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
239000001632 sodium acetate Substances 0.000 claims description 6
235000017281 sodium acetate Nutrition 0.000 claims description 6
JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 claims description 6
239000004324 sodium propionate Substances 0.000 claims description 6
235000010334 sodium propionate Nutrition 0.000 claims description 6
229960003212 sodium propionate Drugs 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims description 4
GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims description 4
GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 4
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
235000019260 propionic acid Nutrition 0.000 claims description 3
229940005605 valeric acid Drugs 0.000 claims description 3
241000792859 Enema Species 0.000 claims description 2
239000007920 enema Substances 0.000 claims description 2
229940095399 enema Drugs 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
230000001747 exhibiting effect Effects 0.000 claims 1
150000004666 short chain fatty acids Chemical class 0.000 abstract description 37
235000021391 short chain fatty acids Nutrition 0.000 abstract description 35
238000000034 method Methods 0.000 abstract description 6
230000002550 fecal effect Effects 0.000 description 10
230000000112 colonic effect Effects 0.000 description 8
210000001072 colon Anatomy 0.000 description 6
239000012530 fluid Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
206010009887 colitis Diseases 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
210000004027 cell Anatomy 0.000 description 4
230000009266 disease activity Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
206010058838 Enterocolitis infectious Diseases 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
201000008243 diversion colitis Diseases 0.000 description 3
210000000224 granular leucocyte Anatomy 0.000 description 3
208000027139 infectious colitis Diseases 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
206010038063 Rectal haemorrhage Diseases 0.000 description 2
206010000269 abscess Diseases 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
-1 alkaline earth metal salts Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000037358 bacterial metabolism Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
210000004922 colonic epithelial cell Anatomy 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
210000004921 distal colon Anatomy 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000008144 emollient laxative Substances 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000003636 fecal output Effects 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000000762 glandular Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

IL9636590A 1989-11-16 1990-11-16 Preparation for the treatment of inflammatory bowel disorders with C6-2 alkanoic acids IL96365A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/438,297 US5039703A (en)	1989-11-16	1989-11-16	Method for treating inflammatory bowel disorders

Publications (2)

Publication Number	Publication Date
IL96365A0 IL96365A0 (en)	1991-08-16
IL96365A true IL96365A (en)	1995-06-29

Family

ID=23740078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9636590A IL96365A (en)	1989-11-16	1990-11-16	Preparation for the treatment of inflammatory bowel disorders with C6-2 alkanoic acids

Country Status (11)

Country	Link
US (1)	US5039703A (de)
EP (1)	EP0502925B1 (de)
AT (1)	ATE143261T1 (de)
AU (2)	AU6681790A (de)
CA (1)	CA2071215C (de)
DE (1)	DE69028712T2 (de)
DK (1)	DK0502925T3 (de)
ES (1)	ES2093695T3 (de)
GR (1)	GR3021760T3 (de)
IL (1)	IL96365A (de)
WO (1)	WO1991007176A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7910624B1 (en)	1995-03-03	2011-03-22	The Trustees Of Boston University	Compositions for the treatment of blood disorders
IT1273628B (it) *	1993-06-04	1997-07-08	Emerging Pharmaceutical Techno	Composizioni farmaceutiche per la cura della talassemia contenenti derivati dell'acido butirrico e in particolare isobutirramide
RO115498B1 (ro) *	1993-10-29	2000-03-30	Univ Boston	Metoda de tratament a neoplasmului
EP0730447B1 (de) *	1993-11-17	2002-02-20	Commonwealth Scientific And Industrial Research Organisation	Fettsäure-abgabesystem
US6011000A (en) *	1995-03-03	2000-01-04	Perrine; Susan P.	Compositions for the treatment of blood disorders
AUPO763197A0 (en) *	1997-06-30	1997-07-24	Sigma Pharmaceuticals Pty Ltd	Health supplement
CA2324426A1 (en) *	1998-02-11	1999-08-19	Douglas V. Faller	Compositions and methods for the treatment of cystic fibrosis
US6114382A (en) *	1998-11-11	2000-09-05	Moretti; Itagiba G.	Methods for treating inflammatory bowel disease
GB0127916D0 (en) *	2001-11-21	2002-01-16	Rowett Res Inst	Method
ITMI20040187A1 (it) *	2004-02-06	2004-05-06	Cosmo Spa	Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
US20070071779A1 (en) *	2005-09-26	2007-03-29	Leggit Ingenuity, Llc	Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
WO2010049954A1 (en) *	2008-10-31	2010-05-06	Lipid Pharmaceuticals Ehf.	Fatty acids for use as a medicament
WO2010105112A1 (en) *	2009-03-11	2010-09-16	Hemaquest Pharmaceuticals, Inc.	Detection of short-chain fatty acids in biological samples
US20110086869A1 (en)	2009-09-24	2011-04-14	The Trustees Of Boston University	Methods for treating viral disorders
US8618068B2 (en)	2009-12-08	2013-12-31	Trustees Of Boston University	Methods and low dose regimens for treating red blood cell disorders
JP4620169B1 (ja) *	2010-01-28	2011-01-26	株式会社三和化学研究所	有機酸重合体を有効成分とするクローン病の予防又は治療剤
US20110245154A1 (en)	2010-03-11	2011-10-06	Hemaquest Pharmaceuticals, Inc.	Methods and Compositions for Treating Viral or Virally-Induced Conditions
EP2971127B1 (de)	2013-03-14	2018-02-28	University Of Ottawa	Verfahren zur diagnose und behandlung von entzündlicher darmerkrankung
CA2962802A1 (en) *	2014-10-03	2016-04-07	University Of Ottawa	Markers for inflammatory bowel disease
US11291693B2 (en)	2015-06-25	2022-04-05	Synlogic Operating Company, Inc.	Bacteria engineered to treat metabolic diseases
JP7373991B2 (ja)	2016-07-15	2023-11-06	ビラクタセラピューティクス，インク．	免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
WO2018027274A1 (en) *	2016-08-10	2018-02-15	Monash University	Metabolites for treatment and prevention of autoimmune disease
JP7136807B2 (ja)	2017-04-17	2022-09-13	ザ・ユニバーシティ・オブ・シカゴ	ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
MX2021014639A (es)	2019-05-31	2022-04-06	Viracta Subsidiary Inc	Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa.
US20240058364A1 (en) *	2020-12-31	2024-02-22	Cannamore Biotechs Ltd.	A composition for use in the treatment of rectal and/or intestinal inflammation
CN116212027A (zh) *	2023-02-28	2023-06-06	西湖大学	一种调控Treg细胞内铁水平的试剂的用途

1989
- 1989-11-16 US US07/438,297 patent/US5039703A/en not_active Expired - Lifetime
1990
- 1990-11-15 CA CA002071215A patent/CA2071215C/en not_active Expired - Fee Related
- 1990-11-15 WO PCT/US1990/006697 patent/WO1991007176A1/en not_active Ceased
- 1990-11-15 AT AT91900102T patent/ATE143261T1/de not_active IP Right Cessation
- 1990-11-15 DE DE69028712T patent/DE69028712T2/de not_active Expired - Fee Related
- 1990-11-15 EP EP91900102A patent/EP0502925B1/de not_active Expired - Lifetime
- 1990-11-15 ES ES91900102T patent/ES2093695T3/es not_active Expired - Lifetime
- 1990-11-15 DK DK91900102.4T patent/DK0502925T3/da active
- 1990-11-16 IL IL9636590A patent/IL96365A/en unknown
- 1990-11-21 AU AU66817/90A patent/AU6681790A/en not_active Abandoned
1993
- 1993-11-08 AU AU50516/93A patent/AU664492B2/en not_active Ceased
1996
- 1996-11-21 GR GR960403149T patent/GR3021760T3/el unknown

Also Published As

Publication number	Publication date
DE69028712T2 (de)	1997-03-20
CA2071215C (en)	1997-02-04
EP0502925A4 (en)	1992-12-16
US5039703A (en)	1991-08-13
DE69028712D1 (de)	1996-10-31
IL96365A0 (en)	1991-08-16
GR3021760T3 (en)	1997-02-28
EP0502925A1 (de)	1992-09-16
AU5051693A (en)	1994-01-13
DK0502925T3 (da)	1996-12-23
AU664492B2 (en)	1995-11-16
ES2093695T3 (es)	1997-01-01
EP0502925B1 (de)	1996-09-25
WO1991007176A1 (en)	1991-05-30
AU6681790A (en)	1991-05-23
ATE143261T1 (de)	1996-10-15
CA2071215A1 (en)	1991-05-17

Legal Events

Date	Code	Title	Description
1997-02-18	KB	Patent renewed
2001-04-30	KB	Patent renewed

Publication	Publication Date	Title
US5039703A (en)	1991-08-13	Method for treating inflammatory bowel disorders
Breuer et al.	1991	Rectal irrigation with short-chain fatty acids for distal ulcerative colitis: preliminary report
US4753964A (en)	1988-06-28	Pharmaceutical compositions of lithium compounds to treat presenile or senile dementia
Wang et al.	1995	Lipid peroxidation accompanies cyclosporine nephrotoxicity: effects of vitamin E
Bergan	1987	Pharmacokinetic properties of the cephalosporins
AU666782B2 (en)	1996-02-22	Schizophrenia
DE69928410T2 (de)	2006-08-03	Selenium enthaltende zusammensetzung zur behandlung von systemischen entzündungssyndromen
Eisen et al.	1961	Uric acid metabolism in psoriasis
Yolken et al.	1976	Acute fluoride poisoning
KR920000324A (ko)	1992-01-29	필수 지방산 처리법
US5569680A (en)	1996-10-29	Method of treating inflammatory bowel disease with tributyrin
Stewart et al.	1976	Further experience with intravesical dimethyl sulfoxide in the treatment of interstitial cystitis
US4910224A (en)	1990-03-20	Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein
Davies et al.	1979	Systemic toxicity from topically applied salicylic acid
Jones et al.	1986	Cathartic-induced magnesium toxicity during overdose management
KR100450293B1 (ko)	2004-11-20	만성장염의치료에유용한알카노일l-카르니틴의용도
Maini	1975	Removal of paraquat from blood by haemoperfusion over sorbent materials
Kandel et al.	1937	Chronic arsenical poisoning during the treatment of chronic myeloid leukemia
US5989558A (en)	1999-11-23	Method of using rosmarinus officinalis for treating various diseases
Abrahamsson et al.	1995	Effect of Short-Term Treatment with Pivalic Acid Containing Antibiotics on Serum Carnitine Concentration-A Risk Irrespective of Age
SEBASTIAN et al.	1968	Renal amyloidosis, nephrotic syndrome, and impaired renal tubular reabsorption of bicarbonate
Novak et al.	1997	Glutamine and other amino acid losses during continuous venovenous hemodiafiltration
Kurata et al.	1991	One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease
Davies	1987	Paraquat poisoning: the rationale for current treatment regimes
Kornbluth et al.	1990	Life-threatening diarrhea after short-term misoprostol use in a patient with Crohn ileocolitis